Rosuvastatin Mylan 10 mg Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rosuvastatin mylan 10 mg

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Rosuvastatin Mylan 20 mg Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rosuvastatin mylan 20 mg

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Rosuvastatin Mylan 40 mg Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

rosuvastatin mylan 40 mg

mylan ireland limited, Írsko - rosuvastatín - 31 - hypolipidaemica

Tramylpa 37,5 mg/325 mg Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

tramylpa 37,5 mg/325 mg

mylan ireland limited, Írsko - tramadol a paracetamol - 65 - analgetica - anodyna

Oroakut s mentolom Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

oroakut s mentolom

mylan ireland limited, Írsko - dichlórbenzylalkohol - 69 - otorhinolaryngologica

Oroakut s príchuťou medu a citrónu Slovakia - slovakki - ŠÚKL (Štátny ústav pre kontrolu liečiv)

oroakut s príchuťou medu a citrónu

mylan ireland limited, Írsko - dichlórbenzylalkohol - 69 - otorhinolaryngologica

Fingolimod Mylan Euroopan unioni - slovakki - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochlorid - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1)orpatients s rýchlo sa meniacim ťažké recidivujúce odosielajúcej roztrúsená skleróza definovaná 2 alebo viac vypnutie relapsami v jednom roku, a s 1 alebo viac gadolínium zvýšenie lézie v mozgu mri alebo významný nárast v t2 lézií zaťažení v porovnaní s predchádzajúcim posledných mri.

Fingolimod Mylan Euroopan unioni - slovakki - EMA (European Medicines Agency)

fingolimod mylan

mylan ireland limited - fingolimod hydrochlorid - roztrúsená skleróza, recidivujúce-odosielajúcej - imunosupresíva - indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4. 4 a 5. 1) or patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.